Merck & Co.
AWARDS
NEWS
For the first time, Merck’s Keytruda beat out Bristol-Myers Squibb’s Opdivo in sales.
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.
Chinese biopharmaceutical company, Changsheng Bio-Technology, is under investigation by Chinese regulators for allegedly falsifying data for a number of products.
Merck presented results from Week 96 of its Phase III DRIVE-FORWARD clinical trial of doravirine in HIV. The data was presented in an abstract at the 22nd International AIDS Conference being held in Amsterdam.
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
JOBS
IN THE PRESS